|
The Daily Briefing · Tuesday, November 17, 2026
|
Anthropic IPO: ANT Prices Wednesday at Up to $1.4T Value
Anthropic prices its IPO Wednesday at $70, $78 a share, valuing it at up to $1.4 trillion, and ANT debuts on Nasdaq Thursday with orders over six times supply.
|
|
Also today
|
AI Hyperscaler Capex Cut Fears Hit 52% in BofA Survey
BofA survey: 52% of fund managers expect an AI hyperscaler to cut capex within six months, up from 30%, as tech overweights fall the most since 2006.
|
Musalem Urges Fed Rate Hikes Sooner as Yields Climb
St. Louis Fed's Alberto Musalem wants fed rate hikes sooner, with 100, 150 basis points of tightening possible by spring 2027, pressuring Treasury yields.
|
CoreWeave, Nebius Drop 7% as AI Stocks Fear Nvidia Shift
Neocloud stocks CoreWeave and Nebius fell about 7, 8% in premarket trading on Monday, with Oracle also lower, as investors weighed Nvidia's AI financing under interim CEO Colette Kress.
|
Gold Hits 13, Month Low Near $3,840 as Dollar Surges
Gold fell to a 13, month low near $3,840 an ounce as the dollar hit its strongest since April 2025 and Fed rate hike bets erased about $400 billion in metals.
|
|
|
More headlines
|
|
Bitcoin Below $65,000 as $2B Liquidations Hit Crypto
Bitcoin fell below $65,000 after roughly $2 billion in leveraged liquidations, as spot ETF outflows mounted and the Fear & Greed Index hit extreme fear.
|
|
US Producer Prices Up 6.5% in October 2026
US producer prices rose 6.5% in October, the fastest since November 2022, lifting the 10, year Treasury yield above 5% and December Fed hike odds to about 95%.
|
|
Fed Rate Hike Odds Near 100% as 10, Year Yield Tops 5%
A December Fed hike is fully priced after hot CPI and Waller's 50 bp remark, lifting the 10, year yield past 5% in its biggest weekly jump since April 2025.
|
|
Nasdaq futures slide as AI stocks fear midterm fallout
Nasdaq futures pointed lower again as investors priced in tighter AI rules and data center pushback after Democrats won both houses of Congress in the midterms.
|
|
Summit Therapeutics Falls as FDA Rejects Lung Cancer Drug
Summit Therapeutics (SMMT) slid premarket after the FDA rejected ivonescimab, its lung cancer drug partnered with Akeso, citing missing overall survival data.
|
|
Brent Near $92 as Oil Slips on Surplus Bets Despite Hormuz
Brent crude slipped toward $92 and WTI toward $85 as traders priced in a supply surplus, despite reported Hormuz mine strikes and the US blockade of Iran.
|
|
Nvidia Q3 FY2027 Earnings: First Report Without Huang
Nvidia reports fiscal Q3 2027 results after the close, its first report without Jensen Huang, as interim CEO Colette Kress faces a $109 billion revenue bar.
|
|
|
Market briefs
|
|
|
|
From the startup desk
|
|
|
|
Video of the day
|
Antimony
|
|
The Daily Briefing from Pomegra. Market news, educational content only. Nothing here is investment advice.
|
|